In the article, “Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond,” which appeared in the May 31, 2005, issue of the journal (Circulation. 2005;111:2837–2849), both Dr Mann and Dr Bristow have ties to industry that were undisclosed and that could be perceived as conflicts of interest. They are as follows:
Dr Mann has stock in and is a consultant for Kardia Therapeutics and is on the Scientific or Product Advisory Board for Biocontrol. He received research support from the NIH and the Veterans Affairs Medical Center.
Dr Bristow has stock in and is a Director of Myogen, Inc., and RCA Discovery, Inc.; has received research support from AstraZeneca, Guidant, Mylan, and Glaxo SmithKline; and has served on Scientific or Product Advisory Boards for Guidant, Genzyme, CVRx, Cardiac Dimensions, Mylan, and Inspiration Medical.